Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of GSK's Cobolimab?
Cobolimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Non-Small Cell Lung Carcinoma;Squamous Non-Small...
Risk adjusted net present value: What is the current valuation of GSK's Cobolimab?
Cobolimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Non-Small Cell Lung Carcinoma;Squamous Non-Small...
Cobolimab by GSK for Cervical Cancer: Likelihood of Approval
Cobolimab is under clinical development by GSK and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Cobolimab by GSK for Metastatic Melanoma: Likelihood of Approval
Cobolimab is under clinical development by GSK and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...
Cobolimab by GSK for Metastatic Colorectal Cancer: Likelihood of Approval
Cobolimab is under clinical development by GSK and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Cobolimab by GSK for Hepatocellular Carcinoma: Likelihood of Approval
Cobolimab is under clinical development by GSK and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II...
Cobolimab by GSK for Colorectal Cancer: Likelihood of Approval
Cobolimab is under clinical development by GSK and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
Cobolimab by GSK for Melanoma: Likelihood of Approval
Cobolimab is under clinical development by GSK and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...